Emory University

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Emory University sits in the top decile of US sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count).

1,208 total trials 208 currently recruiting 767 completed early-phase tilt top decile by trial count

Emory University: 1,208 sponsored US clinical trials, 208 recruiting.

Emory University sponsors 1,208 registered US clinical trials on ClinicalTrials.gov, 208 of them currently recruiting, and 767 completed. 170 of these trials are in Phase 3-4 (later-stage) and 344 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Depression, with 12 trials.

Top-decile sponsor footprint

Emory University ranks in the top decile of sponsors by registered trial count (#24 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 47/100

767 of 926 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (82.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

1,208 total, page 12 of 25

COMPLETED NA

Neural Correlates of Knee Sensorimotor Control in Patients With Patellofemoral Pain Syndrome

NCT04099004

TERMINATED Early Phase 1

Neostigmine For Snoring During DISE

NCT03316963

COMPLETED

A Pilot Study Assessing Intestinal Microbiota Diversification and Changes After Travel to South(East) Asia From the US

NCT03043300

COMPLETED NA

Effects of Dry Needling Using Spinal and Peripheral Sites Versus Peripheral Sites Only

NCT02646579

COMPLETED Phase 3

Treatment of Encopresis in Children With Autism Spectrum Disorders

NCT03197922

COMPLETED

Thyroid Ultrasound Elasticity (TrUE) Imaging

NCT03307694

COMPLETED NA

Standard vs Ultrasound-assisted Catheter Thrombolysis for Submassive Pulmonary Embolism

NCT03086317

TERMINATED Phase 2

Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer

NCT02766478

COMPLETED NA

Open Trial Obesity CHANGE Program ASD

NCT03047018

COMPLETED NA

App Reminder on ASA Adherence

NCT03244267

TERMINATED

Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt

NCT03043339

TERMINATED Phase 2

Effect of VSL#3 on Bone Mineral Density in Postmenopausal Women

NCT03165747

COMPLETED Phase 2

Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma

NCT03137888

COMPLETED NA

Evaluation of an Intervention to Increase Post-abortion LARC Uptake.

NCT03214848

COMPLETED NA

Comparing Mesenchymal Stem Cell Counts in Unilateral vs. Bilateral Posterior Superior Iliac Spine Bone Marrow Aspiration

NCT03014037

COMPLETED NA

A Sleep Intervention (SLEEP-Extend) for Young Adults At-Risk for Type 2 Diabetes

NCT03616171

COMPLETED Phase 2

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

NCT03251495

COMPLETED

Usability and Tolerability of Novel Protection Device Against Potential Brain Injury During Competitive Sport

NCT03318822

COMPLETED Phase 1

Intranasal (NAS) Ketamine for Cancer Pain

NCT03146806

COMPLETED NA

The Morehouse-Emory Cardiovascular Center for Health Equity Study: Clinical Intervention Project

NCT03308812

COMPLETED NA

Microneedle Patch Study in Healthy Infants/Young Children

NCT03207763

COMPLETED Phase 1

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

NCT03095781

TERMINATED Phase 4

Ospemifene vs. Conjugated Estrogens in the Treatment of Postmenopausal Sexual Dysfunction

NCT03018106

COMPLETED Phase 1

A Low ChloridE hyperTonic Solution for Brain Edema

NCT03204955

COMPLETED NA

PreTeenVax Evaluation

NCT03186430

COMPLETED NA

Cryoablation for Obesity Management

NCT03092778

COMPLETED NA

P3+ Intervention Phase

NCT02898688

COMPLETED NA

SMS-Based Follow-Ups to Improve Post-Discharge Surgical Outcomes

NCT03161262

COMPLETED NA

Tool to Improve Treatment Adherence and Outcomes at Grady Liver Clinic

NCT03831555

COMPLETED Phase 2

Study of Genistein in Reducing Side Effects of Superficial Bladder Cancer Treatment

NCT01489813

COMPLETED NA

Testing Tele-Savvy, an On-line Psychoeducation Program for Dementia Family Caregivers

NCT03033875

COMPLETED Phase 4

Glargine U300 Hospital Trial

NCT03013985

TERMINATED Phase 4

Inflammation-Induced CNS Glutamate Changes in Depression

NCT03004443

COMPLETED

Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?

NCT03150069

COMPLETED Phase 2

Autism Oxytocin Brain Project

NCT03033784

COMPLETED Phase 3

Closed Loop Vagal Nerve Stimulation for Patients With Posttraumatic Stress Disorder

NCT02992899

COMPLETED NA

Engaging Patients With Mental Disorders From the ED in Outpatient Care

NCT02989805

TERMINATED Phase 4

Delirium Prevention With Ketamine in Ear, Nose, and Throat (ENT) Patients

NCT03040024

COMPLETED Phase 2

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

NCT03081884

COMPLETED NA

Evaluating Effectiveness of Powered Drill Bone Marrow Biopsy

NCT03078452

COMPLETED NA

Promoting Quality of Life Among Young Adult Cancer Survivors

NCT03446105

COMPLETED Phase 1

Body Compartment PK for New HIV Pre-exposure Prophylaxis Modalities

NCT02985996

COMPLETED NA

Amniotic Membrane for Donor Site Healing

NCT02947737

COMPLETED Phase 2

Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer

NCT02964559

COMPLETED NA

Women Empowered to Live With Lupus Study

NCT02988661

COMPLETED NA

Water Versus Saline as Irrigation Fluid for Ureteroscopy

NCT03794102

COMPLETED Phase 1

Transfusion of Biotinylated Red Blood Cells

NCT02757898

COMPLETED NA

Tailoring of Vaccine-Focused Messages: Disease Salience

NCT03002324

COMPLETED Phase 4

Gabapentin as an Adjunct to Paracervical Block for Perioperative Pain Management

NCT02944656

TERMINATED Phase 1

FMT for MDRO Colonization After Infection in Renal Transplant Recipients

NCT02922816

← Previous Page 12 of 25 Next →

Phase Distribution

PhaseTrial count
Phase 1 154
Phase 2 190
Phase 3 36
Phase 4 134

What is open in the Emory University pipeline

208 recruiting of 1,208 indexed (17% open); 767 completed (63%).

Phase mix: 170 late (III/IV) vs 344 early (I/II) (early-phase heavy).

Top condition: Depression (12 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Emory University: open-pipeline peers nationwide

Peers matched on 1,208 registered trials and 17% open enrollment, not the therapeutic-area sidebar.

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 05001,0001,500 12%14%16%18%20% Total trials Recruiting share Emory UniversityNorthwestern UniversityUniversity of PittsburghNYU Langone HealthUniversity of Alabama at BirminghamBaylor Research InstituteNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Hunter College of City University of New YorkOchsner Health System
Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Emory University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 1,208 trials (± recruiting share)

Sponsors near 17% open enrollment (± trial volume)

What to do with this Emory University page

1,208 registered trials is a research-attention snapshot, not an endorsement of Emory University or any single study.

  • 208 of Emory University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Depression is the condition Emory University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Depression trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Emory University pipeline card: 1,208 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.